Erbitux

News Erbitux

• Merck Withdraws European Filing for Erbitux in NSCLC

  Merck announced the strategic decision to voluntarily withdraw the marketing authorization application (MAA) to the European Medicines Agency (EMA) of a label extension for Erbitux® (cetuximab) in combination with standard first-line platinum-based chemotherapy in patients with advanced or metastati more

• Merck: EXPAND Trial of Erbitux in Advanced Gastric Cancer Does Not Meet Primary Endpoint

  Merck announced the outcome of the Phase III clinical trial EXPAND, which assessed Erbitux® (cetuximab) in combination with cisplatin and capecitabine as a first-line treatment for patients with advanced gastric adenocarcinoma including adenocarcinoma of the gastro-esophageal junction (GEJ). The tri more

• Merck PETACC-8 Study of Erbitux as Adjuvant Treatment in Colon Cancer Shows no Benefit

  Merck announced results from an interim analysis of the Phase III clinical trial PETACC-81. The study investigated the potential clinical utility of Erbitux® (cetuximab) for the adjuvant treatment of stage III colon cancer after complete surgical removal of the primary tumor. The pre-specified inter more

Publications Erbitux

• Pharmacodynamic Modeling of Anti-Cancer Activity of Tetraiodothyroacetic Acid in a Perfused Cell Culture System

  Author Summary Clinical treatment protocols for specific solid cancers have favorable response rates of 20%–25%. Cancer cells frequently become resistant to treatment. Therefore, novel anti-cancer drugs and combination regimens need to be developed. Conducting enough clinical trials to evaluate co more

• Increasing the activity of monoclonal antibody therapeutics by continuous chromatography (MCSGP)

  The charged monoclonal antibody (mAb) variants of the commercially available therapeutics Avastin®, Herceptin® and Erbitux® were separated by ion‐exchange gradient chromatography in batch and continuous countercurrent mode (MCSGP process). Different stationary phases, buffer conditions and two MCSGP more

• Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins

  Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins Nature Biotechnology 28, 863 (2010). doi:10.1038/nbt.1651 Authors: Darius Ghaderi, Rachel E Taylor, Vered Padler-Karavani, Sandra Diaz & Ajit Varki Recombinant glycoprotein therapeutics produ more

Market studies Erbitux

• Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline

  GBI Research, the leading business intelligence provider, has released its latest research, “Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline” which provides insights into the global oncology pipeline. The re more

• Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global nasopharyngeal cancer therapeutics market. The more

• Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology

  GBI Research, the leading business intelligence provider, has released its latest research “Clinical Trial Endpoints in Oncology – Inclusion of Surrogate Endpoints and Shorter Endpoints will Ensure Faster Clinical Trials in Oncology”, which essentially provides insights into clinical trial endpoints more

Websites Erbitux